Introduction {#S1}
============

B-cell cancers hijack protein ubiquitylation and degradation to promote growth and survival, as shown by the successful use of a proteasome inhibitor (bortezomib) and E3 ubiquitin ligase inhibitor (lenalinomide) in multiple myeloma (MM) and mantle cell lymphoma^[@R1]^. Despite the significant progress, much remains to be explored in the field of ubiquitin and molecular mechanisms of tumorigenesis.

Kelch-like protein 6 (KLHL6) is a member of the bric-a-brac/tramtrack/broad-complex (BTB) domain family of proteins with a lymphoid tissue-restricted expression pattern^[@R2],[@R3]^. Whole-genome and exome sequencing have revealed cancer-associated mutations of the *KLHL6* gene in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL)^[@R4]--[@R7]^; however, the relevance of these mutations as well as the molecular function of KLHL6 is currently unknown.

DLBCL is the most common type of lymphoid malignancies with two distinct molecular subtypes: activated B cell-like (ABC) and germinal center B cell-like (GCB) lymphoma^[@R8],\ [@R9]^. ABC-DLBCLs depend on hyper-activation of the inhibitor of IκB kinase (IKK) and the NF-κB transcription factor program for their proliferation and survival^[@R10],\ [@R11]^. This is evidenced by frequent mutations in the BCR pathway, including activating mutations of positive (*CD79A/B* and *CARD11*^[@R12],\ [@R13]^) and inactivating mutations of negative (*TNFAIP3*^[@R12]--[@R15]^) NF-κB regulators. How *KLHL6* contributes to the pathology of human DLBCL and whether it influences NF-κB activation are currently unknown.

Regulatory networks that promote cancer progression modulate gene expression at the level of mRNA stability^[@R16],\ [@R17]^. The RNA‐binding proteins RC3H1 and RC3H2 (from now on Roquin1 and Roquin2) promote mRNA decay via recognition of stem--loop motifs in the 3′ untranslated region (UTR) of target mRNAs^[@R18],\ [@R19]^. Through this recognition, Roquins recruit the CCR4-CAF1-NOT complex, leading to mRNA deadenylation and subsequent destabilization^[@R18]--[@R22]^. In T-cells, Roquin proteins contribute to immune homeostasis by promoting decay of Inducible T-cell Costimulator (ICOS). However, the role of Roquin in B-cell cancers has not been investigated^[@R18],\ [@R23]^.

Here, we demonstrate that KLHL6 is an E3 ligase for Roquin2. Cancer-associated mutations of KLHL6 inhibit its ubiquitin ligase activity and inactivation or loss of KLHL6 in ABC-DLBCL promotes cancer cell growth and survival through stabilization of Roquin2 and subsequent decay of the *TNFAIP3* mRNA. This study shows how ABC-DLBCL cells hijack the ubiquitin pathway to promote their proliferation via alteration of the mRNA decay process.

Results {#S2}
=======

KLHL6 mutations in human DLBCL abolish its catalytic function as cullin3-RING-ligase complex (CRL3) {#S3}
---------------------------------------------------------------------------------------------------

Analysis of genomic databases of human mature B-cell cancer patients revealed mutations of the *KLHL6* gene in DLBCL (<http://cancergenome.nih.gov/> and^[@R4],[@R5],[@R6],[@R7]^), chronic lymphocytic leukemia (CLL)^[@R24]^ and multiple myeloma (MM)^[@R25]^ ([Fig. 1a](#F1){ref-type="fig"}). DLBCL cohorts displayed the highest rate of genetic mutations ([Fig. 1a](#F1){ref-type="fig"}), which are similarly stratified amongst GCB-DLBCL, ABC-DLBCL and uncharacterized DLBCL ([Fig. 1b](#F1){ref-type="fig"}). Most mutations in DLBCL are missense and monoallelic, with a low number in non-sense and frameshift mutations ([Fig. 1c](#F1){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"} and^[@R4],[@R5],[@R6],[@R7]^). Majority of mutations clusters near and inside the BTB-domain of KLHL6 with mutational hotspots in Leucines 65 and 90 ([Fig. 1c](#F1){ref-type="fig"}). Moreover, re-analysis of published SNP array data^[@R26]^ revealed infrequent deletion of the *KLHL6* locus ([Fig. S1a](#SD1){ref-type="supplementary-material"}), while \~6% of DLBCL tumors displayed lower expression of *KLHL6* transcript ([Fig. S1b](#SD1){ref-type="supplementary-material"}).

To understand the impact of these cancer-associated mutations, we compared the protein interactome of KLHL6(WT) to that of the cancer mutant KLHL6(L65P). FLAG-KLHL6(WT) or FLAG-KLHL6(L65P) complexes were immunopurified from two cell lines (HEK293T and ARP-1) and the tryptic digestion of each protein eluate was analyzed by mass spectrometry ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Unique spectral counts corresponding to CULLIN3 were identified in KLHL6(WT), but not in KLHL6(L65P) immunoprecipitates ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

We validated our proteomic analysis via immunoprecipitation of KLHL6 with endogenous CULLIN3, but not CULLIN1, in HEK293T cells ([Fig. 1e](#F1){ref-type="fig"}). By carrying out an *in vitro* ubiquitylation assay, we found that KLHL6 promoted self-ubiquitylation and, notably, its BTB-domain alone \[KLHL6(ΔKelch)\] was sufficient in catalyzing self-polyubiquitylation to a greater degree ([Fig. 1f](#F1){ref-type="fig"}). These data suggest that KLHL6 assembles a functional CULLIN3-RING ubiquitin Ligase (CRL3)^[@R27]^ ([Fig. 1j](#F1){ref-type="fig"}).

We then investigated the effect of DLBCL-associated BTB-domain mutations on KLHL6 ligase assembly and activity. All mutations tested (L65P, S94I, F97L) disrupted binding to CULLIN3 ([Fig. 1g](#F1){ref-type="fig"}) and consequently led to a loss of self-polyubiquitylation *in vitro* ([Fig. 1h](#F1){ref-type="fig"}). Correspondingly, the protein levels of BTB-domain KLHL6 mutants were remarkably high at steady state and displayed extended half-lives as compared to those of wild-type ([Fig. 1i](#F1){ref-type="fig"}), suggesting loss of KLHL6 self-ubiquitylation affects its turnover in cells.

KLHL6 interacts with and promotes the ubiquitylation and degradation of Roquin2 {#S4}
-------------------------------------------------------------------------------

Since KLHL6(L65P) is unable to promote ubiquitylation, we reasoned that it might trap (*i.e.* interact with, but not ubiquitylate) substrates ([Fig. 1j](#F1){ref-type="fig"}). By ranking proteins by the number of unique spectral counts, we identified Roquin2 as a potential substrate ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

In agreement with our proteomic data, KLHL6 specifically co-immunoprecipitated endogenous Roquin2 in HEK293T cells ([Fig. 2b](#F2){ref-type="fig"}). The reciprocal co-immunoprecipitation experiments confirmed Roquin2, but not Roquin1, as a KLHL6 interactor ([Fig. 2c](#F2){ref-type="fig"}). This complex was also detectable at an endogenous level in DLBCL cells ([Fig. S2a](#SD1){ref-type="supplementary-material"}). Importantly, interaction between KLHL6 and Roquin2 required the intact Kelch domain in KLHL6 ([Fig. S2b](#SD1){ref-type="supplementary-material"}), further supporting substrate-like interaction^[@R28]^.

In DLBCL cell lines, abundance of KLHL6 and Roquin2 displayed an inverse correlation ([Fig. 2d](#F2){ref-type="fig"} and [S2c](#SD1){ref-type="supplementary-material"}). To investigate whether KLHL6 controls Roquin2 protein levels, we assessed Roquin2 protein turnover upon knockdown or knockout of KLHL6 in OCI-LY10 and U2932 cells, respectively. In both cases, down-regulation of KLHL6 significantly extended the half-life of Roquin2, but not that of Roquin1 ([Fig. 2e](#F2){ref-type="fig"}, [2f](#F2){ref-type="fig"} and [S2d](#SD1){ref-type="supplementary-material"}).

Gain-of-function experiments showed that re-expression of KLHL6 in cell lines with low *KLHL6* expression (*i.e.;* HEK293T and HBL1, see [Fig. 5a](#F5){ref-type="fig"} right panel) down-regulated Roquin2 protein levels ([Fig. S2e](#SD1){ref-type="supplementary-material"}). Moreover, BTB-domain mutants were incapable of inducing Roquin2 down-regulation ([Fig. S2f](#SD1){ref-type="supplementary-material"}). Notably, co-expression of KLHL6(WT) along with BTB-mutants still promoted Roquin2 degradation, suggesting these mutations are not dominant negative ([Fig. S2g](#SD1){ref-type="supplementary-material"}).

Next, we utilized B-cell lymphoma cell lines harboring endogenous *KLHL6* mutations. VAL cells harbor two BTB-mutations: N60T and T72R ([Fig. 2g](#F2){ref-type="fig"}). Binding analysis revealed that only the KLHL6(T72R) mutant lost interaction with CULLIN3 ([Fig. 2g](#F2){ref-type="fig"}), while KLHL6(N60T) mutant did not. Knockdown of KLHL6 in VAL cells did not result in Roquin2 accumulation ([Fig. 2h](#F2){ref-type="fig"}), whereas re-expression of KLHL6 induced Roquin2 downregulation ([Fig. 2j](#F2){ref-type="fig"}). In VAL cells, expression of *KLHL6* at the mRNA level was comparatively low ([Fig. 2i](#F2){ref-type="fig"}). This suggests that VAL cells display one *KLHL6* allele inactivated by a mutation in the BTB-domain and an additional down-regulation of *KLHL6* mRNA. In contrast, mutations of *KLHL6* in SUDHL10 cells had no impact on KLHL6 function ([Fig. 2g](#F2){ref-type="fig"}, [2h](#F2){ref-type="fig"} 2i, and 2j).

Lastly, to explore whether KLHL6 directly controls Roquin2 ubiquitylation *in vitro*, we incubated immunopurified KLHL6-Roquin2 complex with a ubiquitylation mix. High-molecular weight species of Roquin2 were detected with the KLHL6(WT) complex, but not with KLHL6(L65P) ([Fig. 2k](#F2){ref-type="fig"}). Correspondingly, ubiquitylation of Roquin2 was abolished in *KLHL6^−/−^* cell lines *in vivo* ([Fig. S2h](#SD1){ref-type="supplementary-material"}).

KLHL6 functions as a tumor suppressor in ABC-DLBCL by regulating its growth and survival {#S5}
----------------------------------------------------------------------------------------

Although mutations of *KLHL6* occur at a similar rate in GCB- and ABC-DLBCL ([Fig. 1B](#F1){ref-type="fig"}), low *KLHL6* expression correlated with a significantly poorer survival in ABC-DLBCL patients ([Fig. 3a](#F3){ref-type="fig"}) as previously reported^[@R29],\ [@R30]^.

To assess the biological effect of *KLHL6* loss in ABC-DLBCL lines, we infected Cas9-expressing U2932, OCI-LY10 and TMD8 cells with lentiviruses encoding three different gRNAs targeting the *KLHL6* gene locus. Ablation of *KLHL6* resulted in an increase in cellular proliferation and a decrease in apoptosis ([Fig. 3b](#F3){ref-type="fig"} and [3c](#F3){ref-type="fig"}). This effect was confirmed in 3D cultures as measured by a larger number and size of colonies ([Fig. S3a and S3b](#SD1){ref-type="supplementary-material"}). To rule out the possible off-target effects of gRNAs, we utilized shRNA-mediated knockdown of *KLHL6* in U2932 and OCI-LY10 and observed similar results ([Fig. S3c--f](#SD1){ref-type="supplementary-material"}).

To investigate the role of cancer mutations in cell growth, we re-expressed KLHL6(WT) or KLHL6 BTB-domain mutants or an empty vector (EV) in a clonally-derived U2932 *KLHL6*^−/−^ cell line ([Fig. 3d](#F3){ref-type="fig"}). While re-expression of KLHL6(WT) decreased cell proliferation, expression of KLHL6 BTB-domain mutants phenocopied loss of *KLHL6*, confirming these mutations as loss of function. In xenograft models, expression of KLHL6(WT) decreased tumor burden while expression of KLHL6(S94I) displayed a similar tumor burden compared to *KLHL6*^−/−^ cells (EV) ([Fig. 3e](#F3){ref-type="fig"}).

A non-degradable Roquin2 mutant phenocopies loss of KLHL6 {#S6}
---------------------------------------------------------

We mapped the KLHL6 binding motif in Roquin2. By performing mutagenesis experiments, we identified a region in Roquin2 between amino acids 640 and 700 as necessary for interaction with KLHL6 ([Fig. 4a](#F4){ref-type="fig"} and [4b](#F4){ref-type="fig"}). More refined deletions narrowed the interaction domain between amino acids 690 and 695 ([Fig. 4c](#F4){ref-type="fig"}). Alanine scanning mutagenesis of the individual residues surrounding the 691-704 region revealed that a conserved tyrosine residue, in position 691, was required for KLHL6-Roquin2 interaction ([Fig. 4d](#F4){ref-type="fig"}). *In vitro* binding assays confirmed that a Roquin2 peptide from 686 to 700 directly interacts with KLHL6 ([Fig. S4a--d](#SD1){ref-type="supplementary-material"}). Mutations of tyrosine 691 into alanine or phenylalanine impaired the ability of Roquin2 to co-immunoprecipitate with KLHL6 *in vivo* and *in vitro* ([Fig. 4e](#F4){ref-type="fig"} and [S4c](#SD1){ref-type="supplementary-material"}), suggesting that the integrity of the tyrosine hydroxyl group is critical for KLHL6 interaction.

We retrovirally-transduced BJAB with Roquin2(WT) or Roquin2(Y691F) to investigate whether tyrosine 691 controls Roquin2 stability in DLBCL cells. Roquin2(Y691F) displayed increased protein levels at steady state as well as an extended half-life when compared to that of Roquin2(WT) ([Fig. 4f](#F4){ref-type="fig"} and [S4e](#SD1){ref-type="supplementary-material"}). Furthermore, KLHL6(WT) effectively down-regulated protein levels of Roquin2(WT), but not those of Roquin2(Y691F) ([Fig. S4f](#SD1){ref-type="supplementary-material"}). KLHL6 BTB-mutant(L65P) had no effect on protein levels of Roquin2(WT) and Roquin2(Y691F) ([Fig. S4f](#SD1){ref-type="supplementary-material"}).

Next, we analyzed the effect of Roquin2 stabilization on DLBCL growth. Expression of the non-degradable Roquin2(Y691F) mutant increased tumor burden as monitored by tumor volume and weight at the experimental endpoint ([Fig. 4g](#F4){ref-type="fig"}). This effect was not an artifact of overexpression because the levels of Roquin2(Y691F) were comparable to those of endogenous Roquin2 in *KLHL6^−/−^* cells ([Fig. S4g](#SD1){ref-type="supplementary-material"}). Moreover, knockdown of Roquin2 impaired the cell growth advantage of *KLHL6*^−/−^ U2932 and OCI-LY10 cells ([Fig. 4h](#F4){ref-type="fig"}, and [S4h and S4i](#SD1){ref-type="supplementary-material"}). Importantly, loss of Roquin2 increased toxicity of *KLHL6*^−/−^ cells preferentially ([Fig. S4h](#SD1){ref-type="supplementary-material"}), suggesting that loss of *KLHL6* promotes cell proliferation in a Roquin2-dependent manner.

KLHL6 is a BCR/NF-κB target gene that links Roquin2 degradation to BCR signaling {#S7}
--------------------------------------------------------------------------------

KLHL6 is a member of the B-cell Receptor (BCR)-signalosome^[@R31]^ and is induced upon antigen stimulation in the germinal center^[@R3]^. Thus, we investigated whether mRNA and protein levels of KLHL6 and Roquin2 were affected by BCR stimulation. First, we found ABC-DLBCL cells predominantly expressed an IgM-BCR as opposed to GCB-DLBCL cells, which are positive for IgG-BCR ([Fig. S5a](#SD1){ref-type="supplementary-material"})^[@R32]^. Then, we analyzed levels of KLHL6 and Roquin2 in IgM-positive ABC-DLBCL cell lines (U2932, OCI-LY10 and HBL1) ([Fig 5a](#F5){ref-type="fig"}). BCR stimulation using the fragment affinity-purified antibody F(ab′)2-IgM induced up-regulation of KLHL6 and a corresponding down-regulation of Roquin2 protein levels in OCI-LY10 and U2932, but not in HBL1 \[cell line with low KLHL6 for both mRNA and protein levels ([Fig. 5a](#F5){ref-type="fig"})\].

To demonstrate that BCR-dependent down-regulation of Roquin2 protein depends on CRLs, we pre-treated U2932 cells with MLN4924, a NEDD8-activating enzyme (NAE) inhibitor that blocks Cullin neddylation^[@R33]^. MLN4924 treatment rescued Roquin2 down-regulation induced by BCR-crosslinking, suggesting that a functional CRL-complex is required to promote Roquin2 degradation ([Fig. 5b](#F5){ref-type="fig"}). Notably, BCR stimulation induced KLHL6 up-regulation both at transcriptional and protein levels ([Fig. 5a](#F5){ref-type="fig"}, [5b](#F5){ref-type="fig"} and [5c](#F5){ref-type="fig"}).

Since BCR signaling converges on NF-κB activation^[@R10]^, we investigated whether *KLHL6* is an NF-κB target gene. Analysis of CHIP-Seq datasets of NF-κB factors^[@R34]^ revealed enrichment of p50, p52, RelA and RelB at the *KLHL6* gene locus ([Fig. 5d](#F5){ref-type="fig"}). Correspondingly, treatment of cells with an IKK or a BTK inhibitor (ibrutinib)^[@R13]^, resulted in a down-regulation of KLHL6 both at mRNA and protein levels ([Fig. 5e](#F5){ref-type="fig"}). Interestingly, a reduced sensitivity of *KLHL6*^−/−^ cells to ibrutinib was observed ([Fig. S5b](#SD1){ref-type="supplementary-material"}).

BCR-induced Roquin2 degradation was impaired in *KLHL6*^−/−^ ([Fig. 5f](#F5){ref-type="fig"}) and KLHL6-knockdown cells ([Fig. S5c and S5d](#SD1){ref-type="supplementary-material"}). Correspondingly, while exogenous Roquin2(WT) was degraded in a dose-dependent manner upon BCR stimulation, Roquin2(Y691F) mutant was not affected ([Fig 5g](#F5){ref-type="fig"}), supporting BCR signaling promotes Roquin2 degradation in a KLHL6-dependent manner.

Stabilization of Roquin2 down-regulate BCR responsive genes {#S8}
-----------------------------------------------------------

To investigate whether the pro-proliferative effect of the non-degradable Roquin2(Y691F) mutant depends on its RNA binding ability, we generated a double mutant Roquin2(Y691FΔROQ) lacking the ROQ domain. Notably, deletion of the ROQ domain abolished the growth advantage induced by Roquin2(Y691F) expression ([Fig. 6a](#F6){ref-type="fig"}).

Next, we investigated whether misregulation of Roquin2 degradation would result in a deregulation of the BCR transcriptional program. We measured differential gene expression in U2932 cells expressing Roquin2(WT) or Roquin2(Y691F) upon BCR ligation via RNA-seq ([Fig. 6b](#F6){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Pairwise comparison revealed that 133 mRNAs were significantly down-regulated in Roquin2(Y691F) expressing cells as compared to Roquin2(WT). 64 of these 133 mRNAs overlapped with BCR-responsive genes defined as those with at least a two-fold up-regulation in expression upon BCR stimulation in cells expressing Roquin2(WT) ([Fig. 6b](#F6){ref-type="fig"} and [6c](#F6){ref-type="fig"}). These 64 genes represented BCR responsive genes that failed to be up-regulated upon BCR stimulation in presence of a non-degradable Roquin2 mutant.

Gene ontology (GO) enrichment analysis ([Fig. S6a](#SD1){ref-type="supplementary-material"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}) revealed Roquin2 regulated genes are involved in immune and inflammatory responses and implicated as regulators of the NF-κB pathway and lymphoid tumor suppressors (e.g., *TNF*, *NFKBIE*, *TNFAIP3*, *LTA*, *TNFRSF14*)^[@R14],\ [@R35]--[@R38]^. To identify targets relevant to DLBCL biology, we ranked these genes by the percentage of genetic alterations in human DLBCL (TCGA, <http://cancergenome.nih.gov/>) and the base mean expression in our RNA-Seq analysis ([Fig. S6b](#SD1){ref-type="supplementary-material"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). We validated the top 11 candidates in a secondary screen and found 7 of them were dependent on a functional ROQ domain ([Fig. S6b and c](#SD1){ref-type="supplementary-material"}).

Amongst these targets, we focused on tumor necrosis factor-α-inducible gene 3 (*TNFAIP3*) because it is frequently inactivated in ABC-DLBCLs^[@R12]--[@R15]^ and is a direct target of the Roquin proteins^[@R19]^. We found that *TNFAIP3* was up-regulated upon BCR stimulation consistent with its function as a negative regulator of the NF-κB program ([Fig. 6d](#F6){ref-type="fig"})^[@R39]^. This response was abolished in cells expressing Roquin2(Y691F), suggesting that stabilization of Roquin2 contributes to a reduction of *TNFAIP3* mRNA levels during BCR signaling. This effect was rescued partially in cells expressing Roquin2(Y691FΔROQ) as a build-up of *TNFAIP3* mRNA levels was observed. Notably, other NF-κB target genes (*NFKBIE* and *LTA)* and the tumor suppressor gene *TNFRSF14* displayed a similar pattern.

Lastly, we investigated whether the KLHL6-Roquin2 axis directly controls *TNFAIP3* mRNA stability. Ablation of KLHL6 shortened the half-life of *TNFAIP3*, which was partially rescued by concomitant ablation of Roquin2 ([Fig. 6e](#F6){ref-type="fig"}). Re-expression of KLHL6(WT) in VAL, which carries endogenous BTB-mutations, also increased the half-life of *TNFAIP3* ([Fig. 6e](#F6){ref-type="fig"}).

KLHL6-Roquin2 axis controls NF-κB activation {#S9}
--------------------------------------------

Since KLHL6 regulates *TNFAIP3* mRNA levels, we hypothesized that loss of *KLHL6* would lead to increased NF-κB activation in ABC-DLBCL. First, we investigated whether the *TNFAIP3* transcriptional changes would reflect similar changes in protein levels. BCR dependent degradation of Roquin2(WT) inversely correlated with the up-regulation of TNFAIP3 levels, which was reduced in cells stably expressing Roquin2(Y691F) ([Fig. 7a](#F7){ref-type="fig"}). Correspondingly, TNFAIP3 protein levels were down-regulated in *KLHL6*^−/−^ cells, both at steady state and in response to BCR stimulation ([Fig. 7b](#F7){ref-type="fig"}). Knockdown of Roquin2 in U2932 *KLHL6*^−/−^ cells rescued TNFAIP3 levels similar to those of *KLHL6*^+/+^ cells ([Fig. S7a](#SD1){ref-type="supplementary-material"}). Likewise, depletion of Roquin2 more robustly upregulated of TNFAIP3 protein levels in HBL1 cells ([Fig. 7c](#F7){ref-type="fig"}). Correspondingly, re-expression of KLHL6(WT) in U2932 *KLHL6*^−/−^ cells increased TNFAIP3 levels ([Fig. S7b](#SD1){ref-type="supplementary-material"}).

Next, we investigated whether loss of *KLHL6* resulted in increased IKK activation. The amount of IκBα phosphorylation upon BCR stimulation was higher in *KLHL6*^−/−^ cells, suggesting increased IKK activity ([Fig. 7d](#F7){ref-type="fig"}). Importantly, the increase in phosphorylation was reduced by re-expression of KLHL6(WT) ([Fig. S7c](#SD1){ref-type="supplementary-material"}). We also detected an increase in the nuclear translocation of the NF-κB transcriptional factors in *KLHL6*^−/−^ cells ([Fig. 7e](#F7){ref-type="fig"}), which was partially mitigated by the concomitant knockdown of Roquin2 ([Fig. S7d](#SD1){ref-type="supplementary-material"}). Moreover, ablation of KLHL6 increased RelA DNA-binding at the *NFKBIA* promoter, an effect reversed by simultaneous knockdown of Roquin2 ([Fig. 7f](#F7){ref-type="fig"}).

We analyzed the mutual exclusivity of BTB-associated *KLHL6* mutations with *TNAFAIP3* alterations in DLBCL patients. Deleterious *KLHL6* BTB-mutations showed no overlap with *TNFAIP3* biallelic deletion or mutation ([Fig. 7g](#F7){ref-type="fig"} and [S7e](#SD1){ref-type="supplementary-material"}). Using a weighted test^[@R40]^, we found exclusivity with a trend toward significance (*P*-value 0.085, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). Instead, 4 BTB-mutations had a coincident monoallelic deletion in *TNFAIP3*, suggesting that these mutations might confer additional NF-κB activation when only one *TNFAIP3* allele is lost. Interestingly, tumour cells from patients with *KLHL6* mutations revealed a higher NF-κB activity, although this signature was not only confined to *KLHL6* mutated cases ([Fig. S7f](#SD1){ref-type="supplementary-material"}).

To investigate whether the tumor suppressor role of *KLHL6* would be diminished in *TNFAIP3*-null ABC-DLBCLs, we ablated *KLHL6* in RCK8 cells^[@R14]^ and observed no significant effects on cellular proliferation ([Fig. 7h](#F7){ref-type="fig"}) and apoptosis ([Fig. 7i](#F7){ref-type="fig"}). Additionally, utilizing shRNAs targeting Roquin2 in both HBL1(*TNFAIP3* WT) and HLY1 cells (*TNFAIP3*-null^[@R41]^), we observed elevated apoptosis in HBL1 only ([Fig. 7j](#F7){ref-type="fig"}), indicating the relevance of Roquin2 in cells harboring a functional *TNFAIP3* gene.

Discussion {#S10}
==========

KLHL6 is a BTB-Kelch domain protein mutated in human DLBCL. Somatic mutations localize to the BTB domain with relevant hotspots at amino acids 65 and 90^[@R4]--[@R7]^. Most *KLHL6* alterations in DLBCL include monoallelic missense mutations and infrequent copy loss^[@R4]--[@R7]^. Mutations of *KLHL6* are likely the consequence of aberrant hypersomatic mutation^[@R42]^, similarly to those of BCL6 and MYC^[@R43]^. Importantly, the hotspots and other deleterious BTB-domain mutations result in loss of both CULLIN3 interaction and E3 ligase activity. Data from VAL cells suggest that mutations might be accompanied by a transcriptional down-regulation, resulting in a loss of function. Indeed, about 6% of DLBCL tumors display down-regulation of *KLHL6* transcript. In ABC-DLBCL cell lines, ablation of *KLHL6* promotes cell growth both *in vitro* and *in vivo*, supporting a tumor suppressor role. These findings are consistent with low *KLHL6* expression levels correlating with poorer survival in ABC-DLBCL patients^[@R29],\ [@R30]^.

Furthermore, we identified Roquin2 as the bona fide substrate of KLHL6. KLHL6 specifically binds, ubiquitylates and triggers Roquin2 (but not Roquin1) degradation in a BCR-dependent manner. Expression of a non-degradable Roquin2(Y691F) mutant phenocopies loss of KLHL6 and concomitant ablation of Roquin2 in *KLHL6*^−/−^ cells results in an inhibition of cell proliferation. This pro-proliferative effect depends on the ability of Roquin2 to bind RNA^[@R18]--[@R22]^. Although Roquin1 and Roquin2 are genetically redundant in the T-cell compartment^[@R21]^, no studies have assessed the functional redundancy in B-cell cancers. Transgenic mice overexpressing Roquin2 or the non-degradable mutant in the GC might be helpful to model the oncogenic role of Roquin2 in DLBCL *in vivo.*

*TNFAIP3* is a relevant target of Roquin2-mediated mRNA decay^[@R19]^. In ABC-DLBCL, BCR-signaling triggers transcription of *KLHL6* and degradation of Roquin2, thus releasing *TNFAIP3* from mRNA decay. We speculate that KLHL6 inhibits *TNFAIP3* decay via Roquin2 degradation contributing in establishing a negative feedback loop to terminate the NF-κB signaling ([Fig. 7k](#F7){ref-type="fig"}). Thus, loss of KLHL6 function promotes BCR-dependent activation of NF-κB in ABC-DLBCL. Correspondingly, mutations of *KLHL6* correlate with high NFκB signatures and could serve as a marker of resistance to NFκB pathway targeting drugs such as Ibrutinib^[@R13]^, MLN4924^[@R33]^ or bortezomib^[@R1]^.

*TNFAIP3* genetic mutations and deletions are frequently observed in ABC-DLBCLs^[@R12]--[@R15]^. Functional reconstitution of TNFAIP3 in *TNFAIP3*-null DLBCL causes apoptosis and growth arrest, supporting a tumor suppressor role in DLBCL^[@R44],\ [@R45]^. Interestingly, co-occurrence of *KLHL6* BTB-mutations and *TNFAIP3* biallelic deletion or mutations was rarely observed in human DLBCL, suggesting that these two genes may have similar downstream components (*i.e.* IKK activation). A partial overlap between *KLHL6* BTB-mutations and *TNFAIP3* monoallelic deletion further points to a possible synergy towards NF-κB activation. On the other hand, neither Roquin2 amplification nor sequence alteration of *TNFAIP3* mRNA at the Roquin2 binding site has been observed in DLBCLs. This suggests that the tumor suppressor mechanism of KLHL6 might extend beyond Roquin2/*TNFAIP3* deregulation. It is possible that KLHL6 might be involved in other biological processes such as cell adhesion, migration or immune surveillance in patients.

Much remains in evaluating the functional impact of the KLHL6-Roquin2 axis in GCB-DLBCLs, where unknown KLHL6 substrates or different Roquin2 mRNA targets can contribute to the proliferation and survival of GCB-DLBCL cells. It is also worth noting that *KLHL6* mutations are not observable at high frequency in non-B-cell cancers, suggesting a possibly differential role for KLHL6 in a different genetic and cellular context.

METHODS {#S11}
=======

Cell culture and drug treatment {#S12}
-------------------------------

HEK293T cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS). U2932, BJAB, SUDHL4, SUDHL6, RAMOS, TMD8, HBL1, Pfeiffer, OCI-LY8, Karpas422, ARP1, RCK8, HLY-1, SUDHL10 and VAL were maintained in RPMI 1640 medium containing 10% FBS. OCI-LY1, OCI-LY7, OCI-LY10, and OCI-LY19 were maintained in Iscove's modified Dulbecco's Medium containing 10% FBS. For BCR-crosslinking experiment, Goat-F(ab′)2 anti-human IgM (SouthernBiotech, \#2022-01) was used at indicated concentrations. For 3D matrigel colony formation assay, 150μl of Corning Matrigel Basement Membrane Matrix was used in mix of 100μl of DMEM/F12 containing 10% Knockout Serum Replacement (SR) and plated in Millicell EZ slide (Millipore). For quantification of cell numbers from colonies grown for 14 days, 300μl of Corning Dispase(\#354235) was used according to manufacturers' protocols. The following drugs were used: proteasome inhibitor MG132 (Peptide Institute Inc.; 10 μM final concentration), Cycloheximide (Sigma Aldrich; 50μg/ml final concentration), MLN4924 (Active Biochem; 5μM final concentration), IKK-16(Selleckchem; 10μM final concentration), Ibrutinib((Selleckchem; 5μM final concentration), ActinomycinD (Sigma Aldrich; 2μg/ml final concentration), Doxycycline hyclate(Sigma Aldrich; 1 μg/ml final concentration). When indicated, cells were selected with puromycin(Sigma Aldrich; 0.5μg/ml-1μg/ml final concentration) and hygromycin(ThermoFisher; 100μg/ml). MTS assays (Promega, G5421), AnnexinV staining (Thermo fisher Annexin V, Alexa Fluor® 680 conjugate; A35109) was performed according to manufacturers' protocols. For detection of IgM and IgG surface expression, FITC mouse anti-human IgM (BD, \#562029) and APC mouse anti-human IgG (BD, \#562025) were used according to manufacturing instruction.

### Biochemical methods {#S13}

Extract preparation, immunoprecipitation, and immunoblotting, fractionation of DLBCLs and chromatin immunoprecipitation were carried out according to ref^[@R46]^. Bands quantification was performed using ImageJ software and plotted using nonlinear-fit curve in Prism. All antibodies were used at a dilution of 1:1000 unless specified. The following antibodies were used: anti-FLAG (Sigma, F7425,1:3000), anti-HA (Biolegend, \#901513), anti-Cullin1 (Invitrogen, \#71-8700), anti-Cullin3 (Bethyl Laboratories, A301-109A), anti-ubiquitin K48 (EMD Millipore, 05-1307), anti-Roquin1/2 (EMD Millipore, MABF288), anti-Roquin2(Santa Cruz, sc-165026) anti-Roquin2(Bethyl Laboratories, A305-150A) anti-KLHL6 (Abcam, ab182163), anti-KLHL6(Novus Biologicals, NBP1-46128) anti-Tubulin(Santa Cruz, sc-8035), anti-GAPDH(EMD Millipore, MAB374,1:5000), anti-CDK1(Santa Cruz, sc-954), anti-CDK2(Santa Cruz, sc-163), anti-p-AKT S473 (Cell Signaling Technology, \#4051), anti-p-ERK T202/Y204 (Cell Signaling Technology, \#9101), anti-ERK1/2 (Cell Signaling Technology, \#9102), anti-AKT (Cell Signaling Technology, \#4691), anti-TNFAIP3(Cell Signaling Technology, \#5630), anti-p-IκB S32 (Cell Signaling Technology, \#2859,1:500), anti-p100/p52(Cell Signaling Technology, \#4882), anti-p105/p50(Santa Cruz, sc-7178), anti-RelA(Santa Cruz, sc-372), anti-RelB(Santa Cruz, sc-226), anti-histone H2A(EMD Millipore, 07-146) and anti-histone H3(Abcam, ab1791,1:5000), ECL Rabbit IgG HRP-linked whole antibody(GE healthcare, NA934-1ML,1:5000), ECL Mouse IgG, HRP-linked whole antibody(GE healthcare, NA931-1ML,1:5000), Anti-Rat IgG (H+L) polyclonal antibody(Jackson Immunoresearch, 112-035-003,1:5000), Anti-Goat IgG (H+L) polyclonal antibody(Jackson Immunoresearch, 705-035-003,1:5000). KLHL6, Roquin1/2, TNFAIP3, CULLIN1, CULLIN3, p100/p52, p105/p50 and RelA antibodies were validated in our lab utilizing RNAi as well as overexpression, and were also validated by manufacturer. All other primary antibodies were validated on manufacturer datasheets.

The following agarose beads were used: anti-FLAG-M2 affinity gel (Sigma, A2220) and Strep-Tactin Superflow 50% suspension (Neuromics).

### Xenotransplantation experiments {#S14}

All animal work was performed following the ethical guidelines and protocols approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. NOD/SCID/IL2Rγ−/− (NSG) mice were purchased from the Jackson Laboratory. Six to eight-week-old NSG mice received sub-cutaneous (s.c.) flank injections of 1×10^7^ U2932 KLHL6^−/−^ (clone-derived) cells re-expressed either with empty vector, KLHL6(WT), or KLHL6(S94I)), and 1×10^7^ U2932 cells infected with retroviruses encoding HA-Roquin2(WT) or HA-Roquin2(Y691F) in 100μl sterile PBS. Tumor burden was monitored weekly by palpation and eye inspection. Tumor volume calculated by caliper measurement. Tumor weight was analyzed on the excised tumors at the experimental endpoint using an analytical scale. After about one month, tumor volume and weight were measured.

### Purification and analysis of KLHL6 interactors {#S15}

Approximately 5×10^8^ HEK293T and ARP-1 cells stably expressing FLAG-tagged KLHL6(WT) or FLAG-tagged KLHL6(L65P) cells were harvested and subsequently lysed in lysis buffer (LB: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.5% NP40, plus protease and phosphatase inhibitors). KLHL6 was immunopurified with an anti-FLAG agarose resin (Sigma) and washed five times with LB (15 minutes each). After washing, proteins were eluted with FLAG peptides (Sigma). The eluates (1% of the IP) were separated by SDS-PAGE, and proteins were stained by Silver Staining (Life Technology). The final eluate was then precipitated with trichloroacetic acid (TCA).

### In vitro ubiquitylation assay {#S16}

The ubiquitylation of KLHL6 and Roquin2 was performed in a volume of 10 μl, containing 50 mM Tris pH 7.6, 5 mM MgCl~2~, 2 mM ATP, 1.5 ng/μl E1 (Boston Biochem), 10 ng/μl UBCH5C, 2.5 μg/μl ubiquitin (Sigma), 1 μM ubiquitin aldehyde, and purified FLAG-KLHL6 or FLAG-KLHL6/HA-Roquin2 complex from HEK293T cells via FLAG immunoprecipitation. The reactions were incubated at 37°C for the indicated times, subjected to SDS-PAGE, then analyzed by immunoblot. When indicated, upon reaction, beads were resuspended in 1% SDS, boiled, then diluted to 0.1% SDS. The eluted proteins were further FLAG-immunoprecipitated, washed and eluted in Laemmli buffer before SDS-PAGE analysis.

### In vivo ubiquitylation assay {#S17}

U2932 *KLHL6*^+/+^ and *KLHL6*^−/−^ (clone-derived) cells were treated with or without MG132 for 6hrs and lysed in 1% SDS. Lysates were then diluted to 0.1% SDS in NP-40 buffer and immunoprecipated (IP) with a polyclonal antibody against Roquin2. The immunocomplexes were subjected to SDS-PAGE and analyzed by immunoblot.

### In vitro binding assays {#S18}

For *in vitro* binding assays, *in vitro*-translated FLAG-tagged KLHL6 was added to lysis buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl 0.1% Triton X-100, 1 mM EGTA) with indicated amounts of Roquin2 peptides. Anti-streptavidin resin was then added to the lysis buffer and incubated at 4°C for 2hrs. Samples were washed three times with the lysis buffer, and complexes were eluted in Laemmli buffer. For the use of HEK293T cells stably expressing KLHL6(WT), cells were lysed with the lysis buffer and anti-streptavidin resin was directly added to the whole cell lysates with the peptides.

### Transient transfections and retrovirus-mediated gene transfer {#S19}

HEK293T cells were transfected using polyethylenimine (PEI). For retrovirus and lenvirius production, GP-293 packaging cells (Clontech) or pCMV-DeltaR8.2 were used respectively. The virus-containing medium was collected after forty-eight hours of transfection and supplemented with 10 μg/ml polybrene (Sigma). Then, cells were spin-infected at 1800rpm for 30 minutes with the viral supernatant for six hours to overnight. For RCK8, cells were electroporated using Neon transfection system according to manufacture's protocol with LentiCRISPRv2 vector carrying a GFP marker. Transfected cells were sorted by GFP. siRNA oligos transfection was performed with Neon transfection system.

### Generating clonal KLHL6^−/−^ cell lines {#S20}

U2932 or OCI-LY10 Cas9-expressing cells were infected with lentiviruses encoding gRNAs targeting the *KLHL6* exon1. Upon infection and puromycin selection, cells were plated in a 96 well plate at a concentration of 0.5 cells/well. Single clones were screened for KLHL6 expression by immunoblotting.

### Plasmids {#S21}

Human Roquin1 and Roquin2 cDNA were kindly provided by Dr. Carola Vinuesa and subcloned into pcDNA3.1-FLAG, pcDNA3.1-HA or pcDNA3.1-FLAG-Streptavidin. Human KLHL6 cDNA was purchased from Dharmacon and subcloned into pcDNA3.1-FLAG, pcDNA3.1-FLAG-Streptavidin, pREV-TRE. C-terminal deletion mutants and point mutants were generated by utilizing the QuikChange Site-directed Mutagenesis kit (Stratagene), and N-terminal deletion mutants were generated by standard PCR methods. For retrovirus production, cDNAs encoding FLAG-tagged or HA-tagged KLHL6 and KLHL6 mutants were subcloned into the retroviral vector MIGR1 and pREV-TRE vector. cDNAs encoding FLAG-HA-tagged or untagged Roquin2 and Roquin2 mutants were subcloned into the retroviral vector pBabe Puro or pMSCV. Lentivirus encoding shRNAs targeting human KLHL6 were subcloned in pSicoR-Puro. Lentivirus encoding shRNAs targeting human Roquin2 were subcloned in pSicoR-GFP.

KLHL6 cDNA was clone into pTRIPZ using AgeI and HpaI.

The target sequences used to knock-down human KLHL6 were: hKLHL6_shRNA\#1:For: TGCAGCCAGCAACTATTTCATTCAAGAGATGAAATAGTTGCTGGCTGCTTTTTTCRev:TCGAGAAAAAAGCAGCCAGCAACTATTTCATCTCTTGAATGAAATAGTTGCTGGCTGCAhKLHL6_shRNA\#2:For: TGAAGCCTTGAACCCAGAAATTCAAGAGATTTCTGGGTTCAAGGCTTCTTTTTTCRev:TCGAGAAAAAAGAAGCCTTGAACCCAGAAATCTCTTGAATTTCTGGGTTCAAGGCTTCAhKLHL6_shRNA\#3:For: TGCATGATGTTTGGAAATAT TTCAAGAGAATATTTCCAAACATCATGCTTTTTTCRev:TCGAGAAAAAA GCATGATGTTTGGAAATAT TCTCTTGAAATATTTCCAAACATCATGCAhKLHL6_shRNA\#4:For: TGGATTCAGATTGAGTATTT TTCAAGAGAAAATACTCAATCTGAATCCTTTTTTCRev:TCGAGAAAAAA GGATTCAGATTGAGTATTT TCTCTTGAAAAATACTCAATCTGAATCCA

The target sequences used to knock-down human Roquin2 were: hRoquin2 shRNA\#1:For : TGCAGTTGTCTGCCAATCTATTCAAGAGATAGATTGGCAGACAACTGCTTTTTTCRev:TCGAGAAAAAAGCAGTTGTCTGCCAATCTATCTCTTGAATAGATTGGCAGACAACTGCAhRoquin2 shRNA\#2:For: TGGACTCAGATACCCTTTGATTCAAGAGATCAAAGGGTATCTGAGTCCTTTTTTCRev:TCGAGAAAAAAGGACTCAGATACCCTTTGATCTCTTGAATCAAAGGGTATCTGAGTCCA

Lentiviruses encoding gRNAs targeting human KLHL6 were subcloned into Lenti-Guide-Puro vector, Lenti-Guide-GFP and LentiCRISPRv2 vector. The target sequences to knockout human KLHL6 were: hKLHL6_gRNA\#2For: CAGAGCGTTTTCCATTCGCARev: TGCGAATGGAAAACGCTCTGhKLHL6_gRNA\#3For: TCAGAGCGTTTTCCATTCGCRev: GCGAATGGAAAACGCTCTGAhKLHL6_gRNA\#4For: AAAGGTCAAATTTGACGACGRev: CGTCGTCAAATTTGACCTTThKLHL6_gRNA\#5For: GACTTGGTCGAGATCTTAAARev: TTTAAGATCTCGACCAAGTChKLHL6_gRNA\#6For: ACTTGGTCGAGATCTTAAATRev: ATTTAAGATCTCGACCAAGT

### Gene silencing by siRNA {#S22}

For siRNA-mediated silencing, duplexes were purchased from Dharmacon. The target sequence for human KLHL6 siRNA was GCACGAAGGAUGAACGGUU, The target sequence for human Roquin2 siRNA was GCUUGAAAAGUAUCGAUUA. Non-targeting siRNA control sequence was UGGUUUACAUGUCGACUAA.

### mRNA Analysis {#S23}

RNA was extracted using the RNeasy Kit (Qiagen) and trizol(Invitrogen). cDNA synthesis was performed using Maxima first strand cDNA synthesis kit (Thermo Fisher) and RNA to cDNA Ecodry Premix kit(Clontech). Quantitative PCR analysis with SYBR Green PCR Master Mix (Applied Biosystems) was performed according to standard procedures. Primer sequences were: h*GAPDH*FOR: 5′ GGAGCGAGATCCCTCCAAAAT 3′REV: 5′ GGCTGTTGTCATACTTCTCATGG 3′h*TNFAIP3*FOR: 5′ TCCTCAGGCTTTGTATTTGAGC 3′REV: 5′ TGTGTATCGGTGCATGGTTTTA 3′*hTNFRSF14*FOR: 5′ CCACTGGGTATGGTGGTTTC 3′REV: 5′ TCACCTTCTGCCTCCTGTCT 3′*hTNF*FOR: 5′ CTGCACTTTGGAGTGATCGGC3′REV: 5′ CACCAGCTGGTTATCTCTCAGCTCC 3′h*NFKBIE*FOR: 5′ TCTGGCATTGAGTCTCTGCG 3′REV: 5′ AGGAGCCATAGGTGGAATCAG 3′*hLTA*FOR: 5′ GCTGCTGGTTCTGCTGCC 3′REV: 5′ CAAGGAGAAACCATCCTGGAGGAAG 3′*hNEDD4L*FOR: 5′ ACTTCCTCCTCCTCCTCTGC 3′REV: 5′ TCCAAGTCTTCGCTGATGTG 3′*hABLIM1*FOR: 5′ ACTGCATCTCTCCCTGGCTA 3′REV: 5′ TGTTGGTCACCATGAGCATT 3′*hSYNGAP1*FOR: 5′ TCTGAGGAAAACTGCGAGGT 3′REV: 5′ GCAAACACCTCCTTCAGCTC 3′*hNEIL2*FOR: 5′ GCCTCCACAAAAAGAAGTGC 3′REV: 5′ TTGTTGGCTTTCTTGGCTCT 3′*hLGALS8*FOR: 5′ CTGGGCATTTATGGCAAAGT 3′REV: 5′ GACAGTTCTGGGTGCGATTT 3′*hCD274*FOR: 5′ TATGGTGGTGCCGACTACAA 3′REV: 5′ TGCTTGTCCAGATGACTTCG 3′*hKLHL6*FOR: 5′ GCAGCCAGCAACTATTTCAGG 3′REV: 5′ ACGTGTAGTCCAACAGAGTGT 3′*hNFKBIA*FOR: 5′ TATAAACGCTGGCTGGG 3′REV: 5′ CCCTAGTGGCTCATCGC 3′

### Normalization and quantification of protein levels {#S24}

Protein concentrations of cell extracts were measured using a Bio-Rad DC protein assay (Lowry assay) according to the manufacturer's protocol. For each experiment, equal amounts of protein (\~15μg) were separated by SDS-PAGE and analyzed by immunoblotting. Equal protein levels in each lane were confirmed by Ponceau S staining of the membrane and by immunoblotting a constitutively expressed protein.

### Cell Proliferation Assay {#S25}

2 × 10^3^ cells were plated for MTS assay according to manufacturers' protocols.

For the long-term cell proliferation assay, 5×10^4^-2×10^5^ cells were plated, counted and re-plated every 3--5 days.

### Flow cytometry {#S26}

Flow cytometry was performed on Attune NxT Flow Cytometer using FITC for GFP-expressing cells, Alexa-680 AnnexinV to detect apoptosis, FITC to detect IgM or APC to detect IgG staining. All stainings were performed according to manufacturers' protocols. For investigating shRNA or gRNA effects on survival, 5×10^5^ cells were spin-infected in a 24-well plate with 1000 μl lentivirus containing medium in the presence of polybrene(8μg/ml). Media was changed after the spin-infection and the number of infected cells was determined on day 2 when GFP was fully expressed in all infected cells. The number of viable GFP positive cells on day 2 was set to 100% to normalize for transduction efficiency and every consecutive assessment was calculated in relation to day 2. When indicated, AnnexinV positive cells were gated on GFP positive cells (see gating strategy in [Supplementary Figures 3 and 5](#SD1){ref-type="supplementary-material"}).

### MudPIT analysis {#S27}

TCA-precipitated proteins were urea-denatured, reduced, alkylated and digested with endoproteinase Lys-C (Roche), followed by modified trypsin (Roche), as described^[@R47],\ [@R48]^. Peptide mixtures were loaded onto 100-μm fused silica microcapillary columns packed with 5-μm C18 reverse phase (Aqua, Phenomenex), strong cation exchange particles (Luna, Phenomenex), and reverse phase^[@R49]^. Loaded microcapillary columns were placed in-line with a Quaternary Agilent 1100 series HPLC pump and a LTQ linear ion trap mass spectrometer equipped with a nano-LC electrospray ionization source (Thermo Scientific). Fully automated 10-step MudPIT runs were carried out on the electrosprayed peptides, as described^[@R47]^. Tandem mass (MS/MS) spectra were interpreted using SEQUEST^[@R50]^ against a database of 61,318 sequences, consisting of 30,449 non-redundant human proteins (downloaded from NCBI on 2012-08-27, 160 usual contaminants (such as human keratins, IgGs and proteolytic enzymes), and, to estimate false discovery rates, 30,659 randomized amino-acid sequences derived from each non-redundant protein entry. Peptide/spectrum matches were sorted and selected using DTASelect with the following criteria set: spectra/peptide matches were only retained if they had a DeltCn of at least 0.08 and a minimum XCorr of 1.8 for singly-, 2.0 for doubly-, and 3.0 for triply-charged spectra. In addition, peptides had to be fully tryptic and at least seven amino acids long. Combining all runs, proteins had to be detected by at least two such peptides, or one peptide with two independent spectra. Under these criteria the final FDRs at the protein and spectral levels were 2.1%±0.3 and 0.94% ± 0.03, respectively. Peptide hits from multiple runs were compared using CONTRAST^[@R51]^. To estimate relative protein levels, Normalized Spectral Abundance Factors (NSAFs) were calculated for each detected protein, as described^[@R52],[@R53],[@R54]^.

### Analysis of KLHL6 expression in DLBCL patients {#S28}

Raw DNA copy number data from high resolution single nucleotide polymorphism (SNP) microarray analysis of 609 primary DLBCL tumors were utilized form a previously published study^[@R26]^. The data were visualized using the integrative genomics viewer (IGV)^[@R55]^. Cases were sorted according to their KLHL6 copy number status, and those with copy number \<1.8 were classified as possessing a deletion, according to previously described criteria^[@R56]^.

Gene expression microarray from 249 tumors with matched DNA copy number data were obtained from a previously published study^[@R26]^. Their cell of origin subtype was determined using the Wright algorithm^[@R57]^, as previously reported^[@R56]^. Row normalized heatmaps for 4 probe sets corresponding to KLHL6 were sorted according to their average expression, and significant reduction in KLHL6 expression defined as being 1 standard deviation below the mean.

Raw cel files for publicly available Affymetrix U133 plus 2.0 gene expression microarray data for diffuse large B-cell lymphoma tumors (GSE10846, GSE34171, GSE31312) were obtained from the gene expression omnibus. Data were RMA normalized using the ExpressionFileCreator module of GenePattern^[@R58]^. Scores to categorize diffuse large B-cell lymphoma tumors by cell of origin subtype were calculated according to the Wright algorithm^[@R57]^, Intensities from the 4 probes for KLHL6 (1555275_a\_at, 1560396_at, 1560397_s\_at, 228167_at) were averaged for use in the survival analysis. Cases were dichotomized into being above or below the median expression level of KLHL6 expression within each dataset to avoid confounding batch effects. For NF-κB signatures, Affymetrix U133 plus 2 gene expression microarrays were performed on 84 matched DLBCL tumors^[@R26],[@R59]^. Raw cel files were RMA normalized with median scaling using the ExpressionFileCreator module of GenePattern^[@R58]^. Sample-level enrichment of NF-κB target genes was calculated using the single sample gene set enrichment analysis^[@R60]^ and the c3 TFT gene set database of mSigDB^[@R61]^.

### RNA-seq {#S29}

Total RNA was extracted from U2932 cells using RNeasy Mini Kit (QIAGEN, \#74104) and polyA+ transcripts isolated with oligo (dT)~25~-conjugated magnetic Dynabeads (Thermo Fisher). Strand specific RNA-seq libraries were prepared following a published protocol^[@R62]^. Briefly, RNA was chemically fragmented in first strand buffer, converted to cDNA using SuperScript® III reverse transcriptase (Invitrogen), end-repaired, A-tailed and ligated to custom-designed universal adapters using an end-repair mix, klenow fragment, and T4 DNA ligase (all from Enzymatics). After ligation, adapters were removed by SPRI purification using SPRIselect beads (Beckman coulter) and amplified with Q5 Hot Start DNA polymerase (New England Biolabs) while introducing custom dual indexes. Three biological replicates were sequenced on a NextSeq 500 (Illumina) at a depth of at least 2×10^7^ reads each. Reads were mapped and analyzed with a custom bioinformatic pipeline based on STAR^[@R63]^, SAMTOOLS^[@R64]^, and the R packages DEGseq^[@R65]^ and DEseq2^[@R66]^. We used human genome version GRCh38 and gene annotations from the ENSEMBL release 83. GO analyses were performed using version 6.8 of the DAVID web server^[@R67],\ [@R68]^.

### CHIP-seq {#S30}

The data discussed in this publication were obtained from the NCBI's Gene Expression Omnibus^[@R34]^ and are accessible through GEO at Series accession numbers GSE55105. FASTQs were downloaded and mapped to hg19 with bowtie2 (v2.1.0). Genome browser tracks were generated using custom scripts. When available, biological replicate were merged by taking the mean of the reads density at each position. The data were visualized using the integrative genomics viewer (IGV)^[@R55]^.

### Statistics and Reproducibility {#S31}

All graphs show mean values with error bars signifying standard deviation (s.d.) as indicated in the figure legends. Exact P values for each experiment are provided in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, all immunoblots were successfully repeated at least three times. One-tailed *t*-test was performed for [Fig. 3e](#F3){ref-type="fig"} (right panel) and two-tailed t-test for [Fig 4g](#F4){ref-type="fig"}. Other analyses performed were either one-way ([Fig. 3c](#F3){ref-type="fig"}, [3e](#F3){ref-type="fig"} (left panel), [5e](#F5){ref-type="fig"}, [6a](#F6){ref-type="fig"}, [7i](#F7){ref-type="fig"}, [7j](#F7){ref-type="fig"}, [S3b](#SD1){ref-type="supplementary-material"}, [S3f](#SD1){ref-type="supplementary-material"}) or two-way ANOVA ([Fig. 1i](#F1){ref-type="fig"}, [3b](#F3){ref-type="fig"}, [3d](#F3){ref-type="fig"}, [4g](#F4){ref-type="fig"}, [4h](#F4){ref-type="fig"}, [6e](#F6){ref-type="fig"}, [7h](#F7){ref-type="fig"}, [S2d, S3d, S4e, S4h, S5b](#SD1){ref-type="supplementary-material"}) as indicated in the figure legends. DEseq2 was performed for RNA-seq analysis in [Fig. 6b](#F6){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. Weighted Exclusivity Test (WExT) was performed for [Supplementary Table 5](#SD1){ref-type="supplementary-material"}. Mantel-Cox was performed for survival analysis in [Fig. 3a](#F3){ref-type="fig"}. Pearson Correlation Coefficient was used in [Fig. S2c](#SD1){ref-type="supplementary-material"}.

### Data availability {#S32}

RNA--seq data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) under accession code GSE93675. Previously published CHIP-seq data were obtained from GEO under accession code GSE55105. *KLHL6* copy number change and expression were calculated through re-analysis of SNP data and microarray from GSE11318, GSE12906, GSE15127, GSE22082, GSE34171 and GSE11318, GSE34171, respectively. Microarray data for DLBCL survival were obtained from GEO under accession code GSE10846, GSE34171, GSE31312. Data for NF-κB signature correlation were retrieved from GSE10846. Raw mass spectrometry data are available in PRIDE (<https://www.ebi.ac.uk/pride/archive/>) under accession code PXD008963.

Raw data from independent experiments with n\<5 can be found in the Statistical source data ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Unprocessed immunoblots are provided in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}. All other data supporting the findings of this study are available from the corresponding author on reasonable request.
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![KLHL6 mutations in human DLBCL abolish its catalytic function as CRL3\
**(a)** Percentage of *KLHL6* mutations in patients with diffuse large B-cell lymphoma (DLBCL) \[University of Nebraska Medical Center (UNMC), n=140 patients, The Cancer Genome Atlas (TCGA), n=48, Canada's Michael Smith Genome Sciences Centre (CMSGSC), n= 96, and Broad Institute (Broad), n=58, Duke Cancer Institute (DCI), n= 1001\], Chronic Lymphocytic Leukemia (CLL) \[Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), n=586\] and Multiple Myeloma (MM) (Broad), n=205\].\
**(b)** Percentage of *KLHL6* mutations in DLBCL subtypes. Cohorts from UNMC and CMSGSC were pooled and sub-classified as Activated B-cell-like (ABC)-, Germinal Center B-cell-like (GC)- and Uncharacterized-DLBCL.\
**(c)** Schematic representation of KLHL6 mutations (BTB, Broad-Complex, Tramtrack and Bric-a-brac; BACK, BTB and C-terminal Kelch plant homeodomain).\
**(d)** Proteomic analysis of KLHL6 complex. Spectral counts for CULLIN3 are shown. EV, empty vector. This analysis was performed once in HEK293T and ARP-1 cells.\
**(e)** Immunoblot analysis of immunoprecipitated FLAG-tagged E3 ligases in HEK293T cells. WCL, whole cell lysates. EV, empty vector.\
**(f)** *In vitro* ubiquitylation reaction of immunopurified FLAG-KLHL6 and ΔKelch mutant.\
**(g)** Immunoblot analysis of immunoprecipitated FLAG-tagged KLHL6 wild-type (WT), BTB-mutants (L65P, S94I and F97L), or empty vector (EV) in HEK293T cells.\
**(h)** *In vitro* ubiquitylation reaction of immunopurified FLAG-KLHL6 wild-type (WT) and BTB-mutants (L65P, S94I and F97L).\
**(i)** Immunoblot analysis of whole cell lysates from GFP^+^ OCI-Ly10 *KLHL6*^−/−^ cells (clone-derived) retrovirally transduced with cDNAs encoding an empty vector (EV), KLHL6(WT) or BTB-mutants (L65P, S94I and F97L) and carrying a GFP marker (left panel). Cells were treated with cycloheximide (CHX) for the indicated times. Right panel shows quantification of KLHL6 protein levels (mean±s.d., n=3 independent experiments, two-way ANOVA, \*\*\* P value≤0.001; \*\*\*\*P value≤0.0001).\
**(j)** Schematic model of Cullin3-Ring-Ligase (CRL3)-KLHL6 complex.\
Unprocessed original scan of immunoblots for *(e,f,g,h,i)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and statistical source data and exact P values for *(i)* can be found in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f1){#F1}

![KLHL6 interacts and promotes ubiquitylation and degradation of Roquin2\
**(a)** Proteomic analysis of KLHL6 immunoprecipitations. Spectral counts for Roquin2 proteins are shown. EV, empty vector. The analysis was performed once in two different cell lines (HEK293T and ARP-1).\
**(b)** Immunoblot analysis of immunoprecipitated FLAG-F-box proteins (FBPs) or BTB proteins (BTBPs) in HEK293T cells. Lane 1 shows whole cell lysates (WCL) from cells transfected with an empty vector.\
**(c)** Immunoblot analysis of immunoprecipitated FLAG-Roquin1 or FLAG-Roquin2 in HEK293T cells.\
**(d)** Immunoblot analysis of human DLBCL cell lysates. A low exposure (l.e.) and high exposure (h.e.) are shown. A representative blot from two independent experiments is shown.\
**(e)** Immunoblot analysis of whole cell lysates from OCI-LY10 cells electroporated with indicated siRNAs and treated with cycloheximide (CHX). Quantification and statistical analysis is shown in [Fig. S2d](#SD1){ref-type="supplementary-material"}.\
**(f)** *KLHL6*^+/+^ and *KLHL6*^−/−^ U2932 cells(clone-derived) were processed as in *(e).* A low exposure (l.e.) and high exposure (h.e.) are shown. Quantification and statistical analysis is shown in [Fig. S2d](#SD1){ref-type="supplementary-material"}.\
**(g)** Schematic representation of KLHL6 protein displaying endogenous mutations in VAL and SUDHL10 (top panel). Bottom panel shows immunoblot analysis from immunoprecipitated FLAG-tagged KLHL6 wild-type (WT), KLHL6 mutants (L24R, A25E, N60T, and T72R), or empty vector (EV) in HEK293T cells.\
**(h)** Immunoblot analysis of whole cell lysates from VAL and SUDHL10 cells electroporated with siRNA scramble (siCTRL) or targeting KLHL6 (siKLHL6).\
**(i)** Analysis of level of KLHL6 mRNA by quantitative PCR(qPCR). The value for the PCR product from U2932 cells was set as 1. A representative graph from two independent experiments is shown.\
**(j)** Immunoblot analysis of whole cell lysates from VAL and SUDHL10 cells stably expressing KLHL6 under a doxycycline (DOX) inducible promoter with a puryomycin cassette after 12h of DOX treatment.\
**(k)** *In vitro* ubiquitylation reaction of immunopurified FLAG-KLHL6 and HA-Roquin2.\
Unprocessed original scan of immunoblots for *(b,c,d,e,f,g,h,j,k)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and source data for *(i)* can be found in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f2){#F2}

![KLHL6 functions as a tumor suppressor in ABC-DLBCL by regulating its growth and survival\
**(a)** Kaplan--Meier analysis based on gene expression data for ABC-DLBCL tumors (GSE10846, GSE34171 and GSE3131239-41) is shown (n=367 patients). Censored subjects are indicated on the Kaplan-Meier cure as tick mark. Statistical analysis was performed using the Log-rank (Mantel-Cox), two-sided test, 95% confidence interval.\
**(b)** Cell counts of U2932-, OCI-LY10- and TMD8-Cas9 cells expressing the indicated gRNAs and carrying a puromycin cassette (mean±s.d., n=3 independent experiments, two-way ANOVA, \*P value≤0.05; \*\*P value≤0.01; \*\*\* P value≤0.001; \*\*\*\*P value≤0.0001) (left panel). Cells were grown in media containing 1μg/ml (U2932- and OCI-LY10) or 4μg/ml (TMD8) of F(ab′)2-IgM. Right panel shows immunoblot analysis of whole cell lysates.\
**(c)** Apoptosis analysis of U2932-, OCI-LY10-, and TMD8-Cas9 cells expressing the indicated gRNAs and carrying a GFP marker. Cells were grown as in *(b)*. Apoptosis was quantified on GFP^+^ and Annexin V^+^ cells (mean±s.d., n=3 independent experiments, one-way ANOVA, \*\*P value≤0.01; \*\*\* P value≤0.001).\
**(d)** Left panel shows cell counts of GFP-sorted U2932 *KLHL6*^−/−^ (clone-derived) cells expressing empty vector (EV), KLHL6(WT) or BTB-mutants (L65P, S94I and F97L) and carrying a GFP marker (mean±s.d., n=3 independent experiments, two-way ANOVA, \*\*P value≤0.01; \*\*\* P value≤0.001; \*\*\*\*P value≤0.0001). Right panel shows the immunoblot analysis of whole cell lysates.\
**(e)** Xenograft experiments with GFP-sorted U2932 *KLHL6*^−/−^ cells expressing an empty vector (EV), KLHL6(WT) or KLHL6(S94I) and carrying a GFP marker. Top panel shows the tumors at the experimental endpoint. Tumor volume (mean±s.d., n=5 mice per group, one-way ANOVA, \*P value≤0.05; n.s, not significant) and tumor weight (mean±s.d., n=5 mice per group, one-tailed t-test, \*P value ≤0.05; \*\*P value ≤0.01; n.s, not significant) are shown in the bottom left and right, respectively.\
Unprocessed original scan of immunoblots for *(b,d)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and statistical source data and exact P values for *(a,b,c,d,e)* can be found in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f3){#F3}

![A non-degradable Roquin2 mutant phenocopies loss of KLHL6\
**(a)** Left panel shows immunoblot analysis of immunoprecipitated FLAG-tagged Roquin2 wild type (WT) or mutants in HEK293T cells stably expressing KLHL6. EV, Empty vector. Right panel shows a schematic representation of Roquin2 mutants. Roquin2 mutants that interact (+) or do not interact (-) with KLHL6 are shown. A representative blot from two independent experiments is shown. Asterisk indicates non-specific bands.\
**(b--d)** Same as in *(a).*\
**(e)** Immunoblot analysis of immunoprecipitated FLAG-tagged Roquin2 wild type (WT) or mutants, as indicated, in HEK293T cells stably expressing KLHL6. EV, Empty vector.\
**(f)** Immunoblot analysis of whole cell lysates from a DLBCL cell line, BJAB, retrovirally transduced with cDNAs encoding Roquin2(WT) or Roquin2(Y691F) carrying a puromycin cassette. Cells were treated with cycloheximide (CHX) for the indicated times. Quantification and statistical analysis is shown in [Fig. S4e](#SD1){ref-type="supplementary-material"}.\
**(g)** Top panel shows tumor volume from subcutaneously injected NSG mice with U2932 cells stably expressing retroviruses encoding HA-Roquin2(WT) or HA-Roquin2(Y691F) carrying a puromycin cassette (mean±s.d., n=3 mice per group, two-way ANOVA, \*P value≤0.05; \*\*P value≤0.01; \*\*\* P value≤0.001; \*\*\*\*P value≤0.0001). Bottom panel shows tumor weight (mean±s.d., n=3 mice per group, two-tailed t-test, \*\*\* P value≤0.001).\
**(h)** Cell counts of GFP-sorted U2932 (left panel) or OCI-LY10 (right panel) *KLHL6*^+/+^ and *KLHL6*^−/−^ (clone-derived) cells infected with scramble shRNA(shCTRL) or shRNA targeting Roquin2 (ShRoquin2\#1 or \#2) carrying a GFP marker. GFP^+^ cells were grown in media containing 1μg/ml of F(ab′)2-IgM. (mean±s.d., n=3 independent experiments, two-way ANOVA, \*\*\*\*P value≤0.0001).\
Unprocessed original scan of immunoblots for *(a,b,c,d,e,f)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and statistical source data and exact P values for *(g,h)* can be found in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f4){#F4}

![KLHL6 is a BCR/NF-κB target gene that links Roquin2 degradation to BCR signaling\
**(a)** Immunoblot analysis of whole cell lysates from OCI-LY10, U2932, and HBL1 cells stimulated with 10 μg/ml F(ab′)2-IgM for 3 and 6 hours (left panel). A low exposure (l.e.) and high exposure (h.e.) are shown. Right panel shows level of *KLHL6* mRNA analyzed by qPCR. The value for the PCR product from U2932 was set as 1. A representative graph from two independent experiments is shown.\
**(b)** Immunoblot analysis of whole cell lysates from U2932 cells treated with 10 μg/ml of F(ab′)2-IgM for the indicated times. Where indicated, cells were pre-treated with 5μM MLN4924 for 1 hour.\
**(c)** Analysis of level of *KLHL6* mRNA by qPCR in U2932 cells treated with 10 μg/ml of F(ab′)2-IgM for the indicated times. A representative graph from two independent experiments is shown. The value for PCR product without treatment was set as 1.\
**(d)** Visualization of ChIP-seq peaks using the University of California Santa Cruz (UCSD) Genome browser (GEO Series accession GSE55105). RPM, reads per million mapped.\
**(e)** Same as in *(c)* except that U2932 cells were treated with DMSO, 10μM of IKK inhibitor (IKK-16) or 5μM of BTK inhibitor (Ibrutinib) for 6 hours. The value for PCR product present without treatment (DMSO) was set as 100% (mean±s.d., n=3 independent experiments, one-way ANOVA, \*\*\* P value≤0.001; \*\*\*\*P value≤0.0001). The right panel shows immunoblot analysis of whole cell lysates for the indicated proteins.\
**(f)** Immunoblot analysis of whole cell lysates from U2932 *KLHL6*^+/+^ and *KLHL6*^−/−^ (clone-derived) cells treated with increasing concentrations of F(ab′)2-IgM for 6 hours.\
**(g)** Immunoblot analysis of whole cell lysates from U2932 cells stably expressing HA-Roquin2(WT) or HA-Roquin2(Y691F) treated with F(ab′)2-IgM for 6 hours.\
Unprocessed original scan of immunoblots for *(a,b,e,f,g)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and source data for *(a,c)* and statistical source data and exact P values for *(e)* can be found in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f5){#F5}

![Stabilization of Roquin2 down-regulates BCR responsive genes\
**(a)** Representative image of U2932 cells expressing HA-Roquin2(WT), HA-Roquin2(Y691F) or HA-Roquin2(Y691FΔROQ) with puromycin cassette plated into a matrigel (Left panel). Middle panel shows immunoblot analysis of whole cell lysates and right panel shows cell counts from the matrigel (mean±s.d., n=4 independent experiments, one-way ANOVA, \*\*\*\*P value≤0.0001, n.s, not significant). Scale bar 150μm.\
**(b)** Volcano plot (left panel) showing down-regulated mRNAs (blue) in U2932 cells expressing Roquin2(Y691F) vs Roquin2(WT) upon 12 hours treatment with 10 μg/ml of F(ab′)2-IgM \[log2(fold-change)\<--0.9\]. Down-regulated mRNAs were further plotted in an MA (log ratio, mean average)-plot (right panel). The mRNAs up-regulated upon treatment with F(ab′)2-IgM in cells expressing Roquin2(WT) \[log2(fold-change)\>1\] are shown in red. (n=3 independent experiments, DEseq2, P value\<0.001). NT, non treated.\
**(c)** Venn diagram showing the overlap between genes down-regulated by expression of Roquin2(Y691F) and BCR responsive genes.\
**(d)** qPCR analysis of the indicated mRNAs in U2932 cells expressing HA-Roquin2(WT, Y691F or Y691FΔROQ) treated with 10 μg/ml of F(ab′)2-IgM for indicated times. Value for PCR product present at time 0 hour was set as 1 for each condition. A representative graph from two independent experiments is shown.\
**(e)** qPCR analysis of *TNFAIP3* mRNA in U2932 cells electroporated with indicated siRNAs (left panel) and treated with actinomycinD for the indicated times. The value for PCR product present at time 0 hour was arbitrarily set as 100% (mean±s.d., n=3 independent experiments, two-way ANOVA, \*\*P value ≤0.01, \*\*\*\*P value≤0.0001, n.s, not significant). Same analysis was performed in VAL cells expressing *KLHL6* under a DOX-inducible promoter (Right panel). Cells were pre-treated with DOX for 12 hours and actinomycinD for the indicated times (mean±s.d., n=3 independent experiments, two-way ANOVA, \*P value ≤0.05; \*\*\* P value≤0.001).\
Unprocessed original scan of immunoblots for *(a)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and source data for *(d)* and statistical source data and exact P values for *(a,e)* and *(b)* can be found in [Supplementary Table 6 and 3](#SD1){ref-type="supplementary-material"}, respectively. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f6){#F6}

![KLHL6-Roquin2 axis controls NF-κB activation\
**(a)** Immunoblot analysis of whole cell lysates from U2932 cells expressing HA-Roquin2(WT) or HA-Roquin2(Y691F) treated with 10μg/ml of F(ab′)2-IgM for the indicated times.\
**(b)** Immunoblot analysis of whole cell lysates from U2932 *KLHL6*^+/+^ or *KLHL6*^−/−^ cells (clone-derived) treated with 10μg/ml of F(ab′)2-IgM for the indicated times.\
**(c)** Immunoblot analysis of whole cell lysates from HBL1 cells electroporated with indicated siRNAs and treated as in *(a)* for the indicated times.\
**(d)** Immunoblot analysis of whole cell lysates from U2932 *KLHL6*^+/+^ or *KLHL6*^−/−^ cells (clone-derived) treated with 10μg/ml of F(ab′)2-IgM for the indicated times.\
**(e)** Immunoblot analysis of fractionated U2932 *KLHL6*^+/+^ or *KLHL6*^−/−^ (clone-derived) cells.\
**(f)** RelA ChIP-qPCR for the *NFBKIA* promoter in U2932 *KLHL6*^+/+^, *KLHL6*^−/−^ or *KLHL6*^−/−^ cells infected with indicated shRNAs. Data are displayed as fold enrichment relative to IgG control. A representative graph from two independent experiments is shown.\
**(g)** Overlap of BTB-associated mutations *of KLHL6* with*TNFAIP3* alterations in DLBCLs. Top panel shows tumors sequenced at UNMC^[@R6]^ and DCI^[@R7]^ (n=1175) with deleterious mutations of *KLHL6* in the BTB-domain and *TNFAIP3* mutations. In the bottom panel, the *TNFAIP3* subset is shown as biallelic and monoallelic deletions.\
**(h)** Cell counts of GFP-sorted RCK8 cells expressing Cas9, the indicated gRNAs and a GFP marker. Cells were grown in media containing 1μg/ml of F(ab′)2-IgM (mean±s.d., n=3 independent experiments, two-way ANOVA, n.s, not significant). Right panel shows immunoblot analysis of whole cell lysates.\
**(i)** Apoptosis analysis of cells from *(h)* is shown (mean±s.d., n=3 independent experiments, one-way ANOVA, n.s, not significant).\
**(j)** The percentage of GFP^+^ and AnnexinV^+^ HBL1 and HLY-1 cells expressing the indicated shRNAs is shown (mean±s.d., n=3 independent experiments, one-way ANOVA, \*P value≤0.05; \*\*\* P value≤0.001, n.s, not significant).\
**(k)** Model of KLHL6-Roquin2 axis in ABC-DLBCL.\
Unprocessed original scan of immunoblots for *(a,b,c,d,e,h)* are shown in [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}, and source data for *(f)* and statistical source data for *(h,i,j)* and exact P values for *(j)* can be found in [Supplementary Table 6](#SD1){ref-type="supplementary-material"}. Unless otherwise noted, immunoblots are representative of three independent experiments.](nihms951082f7){#F7}
